Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK3342830
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
GSK3342830 is a novel injectable catechol-cephem (β-lactam) antibiotic developed for the treatment of infections caused by Gram-negative bacteria, including multidrug-resistant isolates. It features enhanced stability to β-lactamases and incorporates a catechol group on its side chain that acts as a siderophore mimetic. This design allows the drug to utilize bacterial iron transport systems for improved penetration into Gram-negative bacteria. Once inside, it inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. The drug was developed by GSK (formerly GlaxoSmithKline) and entered phase 1 clinical trials in 2017 but was discontinued in 2018 due to poor tolerability observed in multiple-dose studies[3][5][6][7].
- Other names
- catechol-cephem antibiotic
02
Targets
TBDT (TonB-dependent outer membrane transporter)PBP3 (Peptidoglycan D,D-transpeptidase FtsI)
Beyond the preview
Go deeper on GSK3342830.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK3342830.